最新消息
News
HanchorBio to Present Encouraging Early Clinical Activity of HCB101 in Combination with Standard-of-Care Therapy for Second-Line Gastric Cancer at ASCO GI 2026漢康生技將於2026 ASCO消化道腫瘤大會發布 HCB101 聯合標準治療在二線胃癌中的早期臨床數據
HanchorBio to Present Encouraging Early Clinical Activi […]
1 月 05, 2026
Read more
HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
HanchorBio Announces Oral Presentation of HCB101 at the […]
12 月 12, 2025
Read more
【Meeting Preview】HanchorBio Announces Oral Presentation of HCB101 at the ESMO Immuno-Oncology Congress 2025
HanchorBio Announces Oral Presentation of HCB101 at the […]
12 月 10, 2025
Read more
HanchorBio Presents First-in-Human Data of HCB101 Monotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma at ASH 2025 漢康生技於 2025 年美國血液學會（ASH）年會發表 HCB101 單藥治療人體試驗結果
HanchorBio Presents First-in-Human Data of HCB101 Monot […]
12 月 09, 2025
Read more
【Meeting Preview】HanchorBio Presents First-in-Human Phase 1 Data of HCB101 at the 67th American Society of Hematology (ASH) Annual Meeting 漢康生技於第 67 屆美國血液學會（ASH）年會公布 HCB101 I 期臨床數據
HanchorBio Presents First-in-Human Phase 1 Data of HCB1 […]
12 月 03, 2025
Read more
HanchorBio Strengthens R&D Strategy with Productive SAB Meeting Focusing on Promising HCB101 Data and Pipeline Innovation
HanchorBio announced the successful completion of its latest Scientific Advisory Board (SAB) meeting. Chaired by Professor Mingyi Chen (UT Southwestern Medical Center), the SAB brings together global leaders from institutions such as The Ohio State University, University of Michigan, Tsinghua University, and National Taiwan University to review HanchorBio’s clinical progress, translational insights, and pipeline strategy across oncology and autoimmune diseases.
10 月 08, 2025
Read more
HanchorBio Strengthens R&D Strategy with Productive SAB Meeting Focusing on Promising HCB101 Data and Pipeline Innovation 漢康生技強化研發策略 聚焦HCB101臨床亮眼數據與創新管線的專家諮詢委員會（SAB）會議圓滿舉行
HanchorBio announced the successful completion of its latest Scientific Advisory Board (SAB) meeting. Chaired by Professor Mingyi Chen (UT Southwestern Medical Center), the SAB brings together global leaders from institutions such as The Ohio State University, University of Michigan, Tsinghua University, and National Taiwan University to review HanchorBio’s clinical progress, translational insights, and pipeline strategy across oncology and autoimmune diseases.
10 月 08, 2025
Read more
HanchorBio Invited to Present at the CBA 27th Annual Conference as the Sole Innovative Drug Company Representing Taiwan
Showcase the Broad Therapeutic Potential of HCB101 in Tumor Immunotherapy
*As the only innovative drug company from Taiwan invited to this year’s CBA Annual Conference, HanchorBio took the international stage to present its AI-assisted Structural Engineering on SIRP-alfa fusion biologic for enhancing Safety and Efficacy, marking an important milestone for Taiwan’s biotech industry.”
*This recognition not only strengthens Taiwan’s position in global AI-assisted drug development, but also opens new opportunities for cross-border licensing and collaboration.
10 月 02, 2025
Read more
HanchorBio Completes the Face-to-Face Scientific Advisory Board Meeting 漢康生技成功舉辦SAB科學顧問委員會會議
HanchorBio Inc. completed a face-to-face Scientific Advisory Board (SAB) meeting on March 29, 2023, in Taipei, Taiwan withworld-renowned professors and few Board of Director (BOD) members.漢康生技（HanchorBio Inc.）於2023年3月29日在台北內湖總部成功舉辦了(SAB)科學顧問委員會會議。
4 月 13, 2023
Read more